Physician profile
Marc Csete
NPI 1861496515
$4,365.29
in general payments reported to CMS, 2019-2025
23 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $2,412 · 2021: $152 · 2022: $380 · 2023: $579 · 2024: $448 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,294 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.76 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $2,360.87 | 2020-2023 | Esbriet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $399.75 | 2019-2025 | Jascayd, Ofev |
| Astrazeneca Pharmaceuticals Lp | $211.78 | 2020-2025 | Fasenra, Tezspire, Breztri |
| Actelion Pharmaceuticals US, INC. | $210.44 | 2019-2022 | |
| Ceribell, INC. | $160.00 | 2020 | |
| Inspire Medical Systems, INC. | $149.68 | 2024 | Inspire |
| Acelrx Pharmaceuticals, INC. | $125.01 | 2020 | |
| Portola Pharmaceuticals, LLC | $79.66 | 2020 | |
| Insmed, INC. | $77.60 | 2021-2025 | Brinsupri, Arikayce |
| Amgen INC. | $75.50 | 2023 | Tavneos |
| United Therapeutics Corporation | $67.06 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $62.81 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $62.42 | 2023-2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $60.54 | 2025 | Acthar |
| Baxter Healthcare | $56.98 | 2024 | Hillrom - Vest System Model 105 Home Care |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $55.30 | 2025 | Yupelri |
| Mylan Specialty L.P. | $43.99 | 2023 | Yupelri |
| Gilead Sciences, INC. | $27.82 | 2023 | Veklury |
| Janssen Pharmaceuticals, INC | $19.85 | 2021 | |
| Pfizer INC. | $19.18 | 2019 | |
| Genzyme Corporation | $17.24 | 2024 | |
| Glaxosmithkline, LLC. | $14.25 | 2024 | Nucala |
| Ambu INC. | $7.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Csete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.